Portuguese 
English 
Spanish 
3 min of reading 
0 comments 
Sam Altman Looks at the Brain Implant Market by Investing in Merge Labs, Elon Musk’s Direct Rival, Expanding the Tech Dispute.
The already intense rivalry between Sam Altman and Elon Musk is gaining a new battleground: the human brain. According to the Financial Times (FT), OpenAI, led by Altman, plans to invest heavily in Merge Labs, a brain implant startup.
The company emerges as a direct competitor to Musk’s Neuralink, the leader in the implantable brain-computer interface (BCI) market.
Sources interviewed by FT claim that the plans are still in the early stages. Merge aims to unite humans and machines through artificial intelligence, leveraging recent advancements in the sector.
-
China creates a capsule with artificial intelligence that scans the stomach in just 8 minutes and can reduce costs by up to R$ 1,400, paving the way for a new era of gastrointestinal diagnostics without tubes, sedation, and discomfort for patients.
-
Scientists simulate nuclear fireball in the laboratory and discover a surprise in the radioactive fallout by observing how cesium, uranium, and cerium change when they remain at high temperatures for a longer time.
-
The Earth’s magnetic pole has decided to “take a trip” towards Russia, getting closer and closer to Siberia, and forcing scientists to update the model used by GPS, airplanes, ships, and military systems worldwide.
-
An underwater volcano on the seafloor off Oregon is showing clear signs of impending eruption, and scientists are observing everything in real-time.
The current valuation is US$ 850 million, with a goal of raising US$ 250 million in funding, most of it coming from OpenAI’s venture capital team.
Co-Founding and Fundraising Goals
Altman is expected to co-found Merge Labs alongside Alex Blania, CEO of Worldcoin. However, he will not make a personal investment in the startup. TechCrunch reports that OpenAI has not yet finalized the commitment, which could alter the terms of the deal.
Altman’s interest in BCIs is not new. In 2017, he published the piece “The Merge,” predicting that the integration of humans and machines could begin as early as 2025.
In a recent post, he reiterated that technological advancements are close to enabling “high bandwidth brain-computer interfaces.”
Neuralink Is Already Testing in Humans
Founded in 2016, Musk’s Neuralink is ahead in human trials. A notable case is Bradford G. Smith, a patient with ALS who lost the ability to speak and move.
With Neuralink’s implant, he can control a computer cursor with his thoughts and communicate. Smith has already used the chip to edit a video and narrate it with synthetic voice created by AI.
The initial success drives ambitious plans. Musk aims to implant the Neuralink chip in 20,000 people per year by 2031. If this target is achieved, the company could generate an estimated annual revenue of US$ 1 billion.
Competition Grows in the Sector
In addition to Merge and Neuralink, other companies are vying for space in the BCI market. Among them are Paradromics, Precision Neuroscience, and Synchron.
Paradromics, for example, completed its first human implant and is advancing towards clinical trials aimed at helping people with severe motor disabilities.
The most important thing is that this movement is not just about technology. It also reflects a personal and business rivalry between Altman and Musk.
The two were co-founders of OpenAI, but Musk left the company in 2018. In 2023, he launched xAI, his own artificial intelligence company.
Conflicts Beyond Technology
This year, Musk sued OpenAI to challenge the transition from a nonprofit organization to a for-profit company. The dispute has also spilled over to the social network X, where Musk and supporters exchanged criticisms of OpenAI.
Furthermore, Musk threatened to sue Apple, accusing it of anti-competitive practices.
In posts on X, he stated that the company would be favoring OpenAI in the App Store, making it difficult for competitors to rise to the top of the AI app rankings.
Calculated Entry into the Market
OpenAI’s move towards Merge Labs appears to be a strategic bet to enter a sector that Musk dominates.
The hope is that the investment could accelerate the development of technologies that bring artificial intelligence even closer to human capability.
Therefore, the rivalry between the two billionaires, which began in artificial intelligence, now extends into a field of high risk and impact.
Brain implants could transform both medicine and the way humans interact with machines, and this race promises to be as intense as the one they are fighting for leadership in AI.
If Merge Labs can progress quickly, it could challenge Neuralink’s leadership and shift the balance of power in the sector. Until then, Altman and Musk will continue to stand on opposite sides of this technological and business dispute, each trying to establish themselves as the pioneer in the direct integration between mind and machine.
Be the first to react!